UNSPSC 51413502: Ibudilast

This classification denotes a vasodilating agent and antiplatelet agent with the molecular formula C14H18N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M0TTH61XC5, chemically known as 3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine but generally known as ibudilast, which bears US NIH Compound Identifier 3671. European Medicines Agency schedules Ibudilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08096MIG.

UNSPSC 51413502 Ibudilast is a Commodity code designating a specific pharmaceutical active ingredient used across state and local emergency medical, pharmacy benefit, and health services procurement. Based on recent opportunities, state and local governments procure ibudilast and related advanced life support medications through competitive sealed bids, cooperative purchasing agreements, and market-research RFIs that encompass broader pharmaceutical supply chains. The City of Tampa's sealed-bid procurement for Advanced Life Support Medications (solicitation 26P00188) exemplifies direct medication procurement by emergency response agencies, requiring vendors to supply specific medication line items with strict expiration and quality warranties. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals demonstrates that state and local governments also aggregate pharmaceutical demand across multiple jurisdictions through cooperative vehicles, requiring manufacturers to meet cGMP, Drug Supply Chain Security Act compliance, and pricing submitted through authorized wholesaler networks. The Texas Health and Human Services Commission's RFI for a Therapeutic Pharmacy Initiative signals emerging state-level interest in direct-to-manufacturer relationships to bypass traditional pharmacy benefit manager and wholesaler intermediaries. Issuing bodies include municipal fire and emergency services departments, state health and human services commissions, and regional cooperative purchasing alliances spanning multiple states and subordinate jurisdictions.

Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP's multistate cooperative reaching into Oregon and other participating members. The City of Tampa's bid (due April 8, 2026, with $40,000 estimated contract value) sought four specific ALS medication line items for Tampa Fire Rescue, requiring nine-month minimum expiration dating and ten-calendar-day delivery, with a one-year base contract term and options to renew. MMCAP's RFP (due March 26, 2026) targeted generic and OTC pharmaceutical manufacturers for multi-year supply agreements effective July 1, 2026, with evaluation weighted heavily toward price competitiveness (75 percent) and compliance with cGMP and DSCSA standards. The Texas HHS RFI (April 3, 2026 response deadline) sought vendor intelligence on direct-to-manufacturer prescription fulfillment models operating outside traditional PBM and wholesaler channels, indicating potential future procurement expansion. All three solicitations emphasize regulatory compliance, pricing transparency, and supply-chain logistics as core vendor qualifications.